Comparative Pharmacology
Head-to-head clinical analysis: MYCIFRADIN versus XEPI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCIFRADIN versus XEPI.
MYCIFRADIN vs XEPI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by causing misreading of mRNA and incorporation of incorrect amino acids into the growing peptide chain.
Ozenoxacin is a topical fluoroquinolone antibiotic that inhibits bacterial DNA replication by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, leading to cell death.
1-2 g orally every 6 hours for 7-14 days. Or 500 mg intramuscularly every 12 hours.
Topical: Apply a pea-sized amount to the affected area twice daily. For moderate to severe plaque psoriasis, initiate treatment with clobetasol propionate spray 0.05% applied twice weekly (Sunday and Thursday) to the scalp and/or body lesions. For plaque psoriasis under occlusion or on limited areas, clobetasol propionate foam 0.05% applied twice daily. For scalp psoriasis, clobetasol propionate shampoo 0.05% applied once daily to the dry scalp, left for 15 minutes, then rinsed. For steroid-responsive dermatoses, clobetasol propionate ointment, cream, or lotion 0.05% applied sparingly to the affected area twice daily (morning and night) for up to 2 weeks; re-evaluate if no improvement. Maximum dose: 50 g/week of 0.05% preparation; for scalp applications, 50 mL/week.
Clinical Note
moderateDoxepin + Desmopressin
"The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin."
Clinical Note
moderateDoxepin + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Doxepin."
Clinical Note
moderateDoxepin + Risedronic acid
"Doxepin can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects."
Clinical Note
moderateNone Documented
None Documented
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may extend to >20 hours in impaired renal function, necessitating dose adjustment.
Terminal elimination half-life is approximately 8 hours in patients with normal renal function (creatinine clearance ≥90 mL/min). In moderate renal impairment (CrCl 30-59 mL/min), half-life extends to about 15 hours.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<1%) with fecal elimination accounting for <1%.
Approximately 80% eliminated renally as unchanged drug via glomerular filtration and tubular secretion. Approximately 20% eliminated in feces via biliary excretion.
Category C
Category C
Antibiotic
Antibiotic
Doxepin + Sodium phosphate, monobasic
"The risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate, monobasic."